Article (Scientific journals)
Results from the Belgian mantle cell lymphoma registry
Vergote, Vibeke; Janssens, Ann; André, Marc et al.
2017In Acta Clinica Belgica, 38, p. 1-7
Peer Reviewed verified by ORBi
 

Files


Full Text
Acta Clinica Belgica-Results from the belgian mantle cell.....pdf
Publisher postprint (697.68 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Mantle cell lymphoma; Registry; Epidemiology; Demographics; Treatment
Abstract :
[en] Introduction: Mantle cell lymphoma is a B-cell non-Hodgkin’s lymphoma characterized by a t(11;14), resulting in overexpression of cyclin D1. Conventional chemotherapy obtains frequent (but short) remissions, leading to a poor median overall survival (OS) of 3–5 years. To obtain more information about the prevalence and current treatment of Mantle cell lymphoma (MCL) in Belgium, we collected data in a Belgian registry of MCL. Materials and methods: All Belgian MCL patients, t(11;14) and/or cyclin D1 positive, seen in hematology departments over a one-year period (April 2013–March 2014) were included. Data about patient characteristics, histology, treatment lines, and response were compiled and retrospectively analyzed. Results: Four hundred and four patients were included with a median age at diagnosis of 64 years (range 23–96 years) and a male predominance (72%). For 2013, we calculated a prevalence of at least 36.2 per million and an incidence of at least 7.0 per million in the Belgian population. Characteristics at diagnosis involved lymphadenopathy (82%), splenomegaly (44%), B-symptoms (39%), and hepatomegaly (10%). Bone marrow invasion was present at diagnosis in 77%. Stage at diagnosis was advanced in the majority of cases. The median number of treatment lines was 1. Type of first line treatment included a combination of anthracyclin and cytarabinebased regimen (34%), anthracyclin (39%), and other. Rituximab was used in 88% of first line treatments. In 44% first line treatment was followed by autologous stem cell transplantation. Conclusion: The analysis of this Belgian MCL registry provides insight in the epidemiology, demographics, and current treatment of our Belgian MCL population.
Disciplines :
Hematology
Author, co-author :
Vergote, Vibeke
Janssens, Ann
André, Marc
Bonnet, Christophe ;  Université de Liège > GIGA-R : Hématologie
Van Hende, Vanessa
Van Den Neste, Eric
Van Eygen, Koen
Maerevoet, Marie
Pranger, Delphine
Schroyens, Wilfried
Debussche, Sarah
Maertens, Vincent
Beel, Karolien
Lemmens, Jan
Caron, Charlotte
Delrieu, Vanessa
Van Den Broeck, Isabelle
Vanstraelen, Gaetan
Jacquy, Caroline
Schauvlieghe, Liesbeth
De Samblanx, Hade
Madoe, Vincent
Meers, Stef
Boulet, Dominique
Verhoef, Gregor
Van Hoof, Achiel
More authors (16 more) Less
Language :
English
Title :
Results from the Belgian mantle cell lymphoma registry
Publication date :
22 February 2017
Journal title :
Acta Clinica Belgica
ISSN :
0001-5512
Publisher :
Acta Clinica Belgica, Bruxelles, Belgium
Volume :
38
Pages :
1-7
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 23 January 2018

Statistics


Number of views
205 (7 by ULiège)
Number of downloads
343 (4 by ULiège)

Scopus citations®
 
3
Scopus citations®
without self-citations
3
OpenCitations
 
2

Bibliography


Similar publications



Contact ORBi